Session 1: Challenges in screen detected early cancers
Prediction models for lymph node metastasis
Miangele Lacle, the Netherlands
Evaluation of the resection margin- is 1 mm sufficient?
Maurice Laughry, Ireland
What is coming next in the prediction of LNM-
Cord Langner, Austria
Session 2: What’s new in diagnostic imaging – and what are the therapeutic consequences?
Locoregional staging of colon and rectal cancer
Regina Beets-Tan, the Netherlands
Imaging modalities for liver metastases
Doenja Lambregts, the Netherlands
New diagnostic tools: radiomics, “deep learning” – really helpful?
until 16:30 hrs. // Parallel program – Gastroenterology
Select the menu scientific program >> Sunday 10 March parallel program – Gastroenterology for more information about the programme.
Session 3: State of the art and development in neo-adjuvant treatment
Difference between cCR after CRT for advanced rectal cancer and aiming for cCR with CRT in early rectal cancer
Rob Glynne-Jones, United Kingdom
Is chemotherapy going to replace radiotherapy in rectal cancer?
David Sebag Montefiore, United Kingdom
Deciding on further local treatment after induction therapy for local and metastatic disease; value and timing of re-staging modalities
Geerard Beets, the Netherlands
Lunch & Poster viewing
CRC Group Meetings / Trial Meetings / Consensus or Guideline initiatives
InterAACT: A global initiative in anal cancer
Sheela Rao, United Kingdom
Presentation of CIREL and CIEMAR registries
Philippe Pereira, Germany
Translational research: from bench to bedside and back
Onno Kranenburg, the Netherlands (more information about the program, please expand the menu)
12:45 From Tissue towards Liquid biopsy: current status
Marc Peeters, Belgium
13:00 The serrated pathway: implications for research
Iris Nagtegaal, the Netherlands
13:15 Translational research: from bench to bedside and back
Onno Kranenburg, the Netherlands
13:30 Selected abstract to be announced
Session 4: Case discussion with expert panel
Session 5: Translational research: From markers to decisions
Clinical implications of “liquid” markers (ctDNA) for treatment selection and response evaluation
Karen-Lise Spindler, Denmark
Clinical implications of tissue-based markers (CMS and others)
Louis Vermeulen, the Netherlands
Organoids to assess treatment response
Nicola Valeri, United Kingdom
Session 6: What’s new in diagnostic and therapeutic endoscopy?
State of the art optical diagnosis of polyps
Jara Backes, the Netherlands
Endoscopic and surgical techniques for local excision in rectal cancer, what should we do?
Endoscopic and hybrid techniques for local excision of colon cancer
Leon Moons, the Netherlands